Polypill and colchicine for heart and artery risk
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a combination pill (polypill) and a medicine called colchicine to see if they can lower the risk of future heart attacks, strokes, or other artery problems. It is for people who already have a history of heart or blood vessel disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 45 years old or older.
- You have had a heart attack, stroke, or a procedure to open a blocked artery, or you have a major artery blockage (50% or more).
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You do not have advanced kidney or liver disease, or a muscle disease.
- You are not taking blood thinners (except for a low dose of rivaroxaban for peripheral artery disease) or colchicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a daily low dose of colchicine, a medicine used for gout and inflammation, can reduce inflammation and improve blood vessel and bone health in people with chronic kidney disease. It might help prevent complications like heart disease and weak bones.
This trial tests whether a daily low-dose of colchicine, a common anti-inflammatory medicine, can help prevent heart attacks and strokes in people with type 2 diabetes who do not yet have heart disease. If it works, it could be a simple addition to your current diabetes care.
This trial tests whether a low dose of the anti-inflammatory drug colchicine can help people who have recently had a heart attack or unstable angina. It aims to see if colchicine reduces the risk of future heart problems.
This trial tests if colchicine, a common anti-inflammatory medicine, can help prevent future heart problems in people who have coronary artery disease and recently had a stent placed. It's for adults with at least one extra risk factor like diabetes, smoking, or high blood pressure.
This trial tests whether low-dose colchicine can reduce “residual” risk—future heart and blood-vessel problems—in people with peripheral artery disease (PAD). It targets PAD symptoms and complications like poor blood flow in the legs, even after certain procedures.
This trial is for people who had a heart attack and received a specific type of stent (Orsiro). It tests a combination of a single antiplatelet drug and colchicine to see if it helps prevent future heart problems. Colchicine is a medicine that reduces inflammation and might lower the risk of another heart attack.
Hear when a new Atherosclerotic Cardiovascular Disease (ASCVD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.